D. Richardson

发表

The new role of poly (rC)-binding proteins as Iron transport chaperones: Proteins that could couple with inter-organelle interactions to safely traffic iron.

I. Yanatori, D. Richardson, S. Toyokuni, 2020, Biochimica et biophysica acta. General subjects.

How iron is handled in the course of heme catabolism: Integration of heme oxygenase with intracellular iron transport mechanisms mediated by poly (rC)-binding protein-2.

I. Yanatori, D. Richardson, S. Toyokuni, 2019, Archives of biochemistry and biophysics.

Iron Chelator-Mediated Alterations in Gene Expression: Identification of Novel Iron-Regulated Molecules That Are Molecular Targets of Hypoxia-Inducible Factor-1α and p53

D. Richardson, F. Saletta, Y. Suryo Rahmanto, 2010, Molecular Pharmacology.

Cellular Iron Depletion Stimulates the JNK and p38 MAPK Signaling Transduction Pathways, Dissociation of ASK1-Thioredoxin, and Activation of ASK1*

D. Richardson, Yu Yu, Des R. Richardson, 2011, The Journal of Biological Chemistry.

Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come

D. Richardson, Phatsapong Yingchoncharoen, D. Kalinowski, 2016, Pharmacological Reviews.

The metastasis suppressor, NDRG1, differentially modulates the endoplasmic reticulum stress response.

D. Richardson, A. M. Merlot, G. Porter, 2019, Biochimica et biophysica acta. Molecular basis of disease.

Investigating the Spectrum of Biological Activity of Ring-Substituted Salicylanilides and Carbamoylphenylcarbamates

D. Richardson, D. Kalinowski, F. Šeršeň, 2010, Molecules.

P-glycoprotein Mediates Drug Resistance via a Novel Mechanism Involving Lysosomal Sequestration*

D. Richardson, S. Sahni, A. Arvind, 2013, The Journal of Biological Chemistry.

Guidelines for the use and interpretation of assays formonitoring autophagy (3rd edition)

Sangeeta Khare, Xin Qi, Ying Wang, 2016 .

In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites

D. Richardson, K. Vávrová, D. Kalinowski, 2015, PloS one.

The Iron Chelators Dp44mT and DFO Inhibit TGF-β-induced Epithelial-Mesenchymal Transition via Up-Regulation of N-Myc Downstream-regulated Gene 1 (NDRG1)

M. Zheng, Daohai Zhang, D. Richardson, 2012, The Journal of Biological Chemistry.

Unraveling the mysteries of serum albumin—more than just a serum protein

D. Richardson, D. Kalinowski, A. Merlot, 2014, Front. Physiol..

A Nitric Oxide Storage and Transport System That Protects Activated Macrophages from Endogenous Nitric Oxide Cytotoxicity*

D. Richardson, S. Sahni, C. Hawkins, 2016, The Journal of Biological Chemistry.

Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.

D. Richardson, T. Chaston, D. Lovejoy, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Identification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography–quadrupole-time-of-flight mass spectrometry

J. Klimeš, D. Richardson, D. Kalinowski, 2013, Analytical and Bioanalytical Chemistry.

LC-MS/MS identification of the principal in vitro and in vivo phase I metabolites of the novel thiosemicarbazone anti-cancer drug, Bp4eT

J. Klimeš, M. Nobilis, D. Richardson, 2012, Analytical and Bioanalytical Chemistry.

Role of Glutaredoxin1 and Glutathione in Regulating the Activity of the Copper-transporting P-type ATPases, ATP7A and ATP7B*

D. Richardson, Yu Yu, J. Mercer, 2010, The Journal of Biological Chemistry.

protein kinase in skeletal muscle Energy-sensing and signaling by AMP-activated

C. S. Bickel, B. Lay, J. Rubenson, 2015 .

Effect of iron chelators with potent anti-proliferative activity on the expression of molecules involved in cell cycle progression and growth.

D. Richardson, D. Lovejoy, J. Gao, 1999, Redox report : communications in free radical research.

Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents.

D. Richardson, J. Kwok, Des R. Richardson, 2004, Molecular pharmacology.

The metastasis suppressor NDRG1 directly regulates androgen receptor signaling in prostate cancer

D. Richardson, Z. Kovacevic, Bekesho Geleta, 2021, The Journal of biological chemistry.

The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways*

D. Richardson, D. Kalinowski, S. Sahni, 2015, The Journal of Biological Chemistry.

The role of NDRG1 in the pathology and potential treatment of human cancers

D. Richardson, C. S. Lee, D. Kalinowski, 2013, Journal of Clinical Pathology.

The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms.

Daohai Zhang, D. Richardson, Z. Kovacevic, 2011, Carcinogenesis.

Biphasic effects of l-ascorbate on the tumoricidal activity of non-thermal plasma against malignant mesothelioma cells.

M. Mizuno, M. Hori, D. Richardson, 2016, Archives of biochemistry and biophysics.

Lysosomal membrane stability plays a major role in the cytotoxic activity of the anti-proliferative agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT).

D. Richardson, D. Kalinowski, S. Sahni, 2016, Biochimica et biophysica acta.

Novel SPME fibers based on a plastic support for determination of plasma protein binding of thiosemicarbazone metal chelators: a case example of DpC, an anti-cancer drug that entered clinical trials

D. Richardson, D. Kalinowski, J. Roh, 2019, Analytical and Bioanalytical Chemistry.

Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy.

D. Richardson, D. Kalinowski, 2007, Chemical research in toxicology.

Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97 (Melanotransferrin): no overt alteration in phenotype.

D. Richardson, Y. Suryo Rahmanto, 2009, Biochimica et biophysica acta.

Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo.

D. Richardson, Y. Suryo Rahmanto, L. Dunn, 2006, Blood.

Exploring the Anti-Cancer Activity of Novel Thiosemicarbazones Generated through the Combination of Retro-Fragments: Dissection of Critical Structure-Activity Relationships

J. Gołąb, J. Polanski, D. Richardson, 2014, PloS one.

The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of &bgr;-catenin through mechanisms involving FRAT1 and PAK4

M. Zheng, D. Richardson, Z. Kovacevic, 2014, Journal of Cell Science.

Investigating the anti-proliferative activity of styrylazanaphthalenes and azanaphthalenediones.

J. Polanski, D. Richardson, J. Rzeszowska-Wolny, 2010, Bioorganic & medicinal chemistry.

Mitochondrial Iron Metabolism and Sideroblastic Anemia

D. Richardson, J. Prchal, P. Ponka, 2009, Acta Haematologica.

Cytosolic phospholipase A2α sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells.

Marzieh Niknami, D. Richardson, P. Witting, 2013, Biochimica et biophysica acta.

Two mechanisms involving the autophagic and proteasomal pathways process the metastasis suppressor protein, N-myc downstream regulated gene 1.

D. Richardson, K. Park, S. Sahni, 2019, Biochimica et biophysica acta. Molecular basis of disease.

Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion.

D. Richardson, Dong Fu, 2007, Blood.

Richardson cell-cycle progression as effective antiproliferative agents , IV : the mechanisms involved in inhibiting The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone

D. Richardson, Jin Gao, 2001 .

Targeting Dys-Regulated Reactive Oxygen Species Homeostasis in Cancer as a Selective Chemotherapeutic Approach

D. Richardson, D. Kalinowski, 2012 .

Intermediate steps in cellular iron uptake from transferrin. II. A cytoplasmic pool of iron is released from cultured cells via temperature-dependent mechanical wounding

D. Richardson, L. Dickson, E. Baker, 1996, In Vitro Cellular & Developmental Biology - Animal.

Molecular and functional alterations in a mouse cardiac model of Friedreich ataxia: activation of the integrated stress response, eIF2α phosphorylation, and the induction of downstream targets.

Daohai Zhang, D. Richardson, C. Semsarian, 2013, The American journal of pathology.

Interactions of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: implications for toxicity in the treatment of iron overload disease

D. Richardson, T. Chaston, 2003, JBIC Journal of Biological Inorganic Chemistry.

Ferritinophagy and ferroptosis in the management of metabolic diseases

P. Libby, D. Klionsky, G. Kroemer, 2021, Trends in Endocrinology & Metabolism.

Innovative Therapies for Neuroblastoma: The Surprisingly Potent Role of Iron Chelation in Up-Regulating Metastasis and Tumor Suppressors and Down-Regulating the Key Oncogene, N-myc.

D. Richardson, Tharushi P Wijesinghe, M. Dharmasivam, 2021, Pharmacological research.

Structure-Activity Relationships of Novel Salicylaldehyde Isonicotinoyl Hydrazone (SIH) Analogs: Iron Chelation, Anti-Oxidant and Cytotoxic Properties

D. Richardson, K. Vávrová, D. Kalinowski, 2014, PloS one.

More roles for selenoprotein P: local selenium storage and recycling protein in the brain.

D. Richardson, 2005, The Biochemical journal.

The uptake of iron and transferrin by the human malignant melanoma cell.

D. Richardson, E. Baker, Des R. Richardson, 1990, Biochimica et biophysica acta.

William Hunter and radioiodination: Revolutions in the labelling of proteins with radionuclides of iodine

D. Richardson, D. Lane, 2011 .

Function and regulation of transferrin and ferritin.

C. Beaumont, D. Richardson, P. Ponka, 1998, Seminars in hematology.

The old and new biochemistry of polyamines.

D. Richardson, P. Jansson, D. Lane, 2018, Biochimica et biophysica acta. General subjects.

Identification of a mechanism of iron uptake by cells which is stimulated by hydroxyl radicals generated via the iron-catalysed Haber-Weiss reaction.

D. Richardson, P. Ponka, Des R. Richardson, 1995, Biochimica et biophysica acta.

Structure-Activity Relationships of Di-2-pyridylketone, 2-Benzoylpyridine, and 2-Acetylpyridine Thiosemicarbazones for Overcoming Pgp-Mediated Drug Resistance.

D. Richardson, D. Kalinowski, P. Bernhardt, 2016, Journal of medicinal chemistry.

A novelironuptakemechanismmediated by GPI-anchored humanp97

D. Richardson, M. Kennard, R. Gabathuler, 1995 .

S-Nitrosylated S 100 A 8 : Novel Anti-Inflammatory Properties 1

D. Richardson, M. Raftery, C. Geczy, 2008 .

S-Nitrosylated S100A8: Novel Anti-Inflammatory Properties1

D. Richardson, M. Raftery, C. Geczy, 2008, The Journal of Immunology.

Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia

Lucía Gutiérrez, F. Lázaro, T. S. St. Pierre, 2012, Proceedings of the National Academy of Sciences.

Growth arrest and DNA damage-45 alpha (GADD45alpha).

D. Richardson, A. Rosemary Siafakas, 2009, The international journal of biochemistry & cell biology.

ERp29 induces breast cancer cell growth arrest and survival through modulation of activation of p38 and upregulation of ER stress protein p58IPK

Daohai Zhang, T. Putti, D. Richardson, 2012, Laboratory Investigation.

Resistance to the Antineoplastic Agent Gallium Nitrate Results in Marked Alterations in Intracellular Iron and Gallium Trafficking: Identification of Novel Intermediates

D. Richardson, C. Chitambar, N. Davies, 2006, Journal of Pharmacology and Experimental Therapeutics.

Cellular Uptake of the Antitumor Agent Dp44mT Occurs via a Carrier/Receptor-Mediated Mechanism

D. Richardson, D. Kalinowski, S. Sahni, 2013, Molecular Pharmacology.

Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase.

D. Richardson, W. Antholine, S. J. Wong, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Regulation and control of nitric oxide (NO) in macrophages: Protecting the "professional killer cell" from its own cytotoxic arsenal via MRP1 and GSTP1.

D. Wink, D. Richardson, S. Sahni, 2017, Biochimica et biophysica acta. General subjects.

Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes.

D. Richardson, P. Ponka, H. Schulman, 1988, Biochimica et biophysica acta.

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

Mark R. Marten, Erinna F. Lee, Dana L. Miller, 2021, Autophagy.

The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression.

Jin Gao, D. Richardson, J. Gao, 2001, Blood.

Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity.

D. Richardson, P. Bernhardt, P. Jansson, 2010, Journal of medicinal chemistry.

Bonnie and Clyde: Vitamin C and iron are partners in crime in iron deficiency anaemia and its potential role in the elderly

D. Richardson, P. Jansson, D. Lane, 2016, Aging.

Cellular and Molecular Biology of Iron-Binding Proteins

D. Richardson, D. Kalinowski, 2010 .

Ferroportin1: a new iron export molecule?

D. Richardson, N. T. T. Le, 2002, The international journal of biochemistry & cell biology.

Cloning of the ferrireductase that may be involved in iron transport in the small intestine: revisiting Crane's controversial oxidoreductase

D. Richardson, 2001, Redox report : communications in free radical research.

Sustained expression of heme oxygenase-1 alters iron homeostasis in nonerythroid cells.

D. Richardson, B. Halliwell, R. Stocker, 2012, Free radical biology & medicine.

Iron and gallium increase iron uptake from transferrin by human melanoma cells: further examination of the ferric ammonium citrate-activated iron uptake process.

D. Richardson, 2001, Biochimica et biophysica acta.

Potent Antitumor Activity of Novel Iron Chelators Derived from Di-2-Pyridylketone Isonicotinoyl Hydrazone Involves Fenton-Derived Free Radical Generation

D. Richardson, T. Chaston, Jun Yuan, 2004, Clinical Cancer Research.

Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment.

D. Richardson, Jun Yuan, D. Lovejoy, 2004, Blood.

Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells.

D. Richardson, D. Lovejoy, 2002, Blood.

Transferrin iron uptake is stimulated by ascorbate via an intracellular reductive mechanism.

D. Richardson, D. Lane, Sherin Chikhani, 2013, Biochimica et biophysica acta.

REVIEW Fixing frataxin: ‘ironing out’ the metabolic defect in Friedreich’s ataxia

D. Richardson, D. Lane, M. Huang, 2014 .

Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood.

P. Kuchel, D. Richardson, Y. Suryo Rahmanto, 2009, Blood.

Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: examination of the intermediates involved in iron metabolism.

D. Richardson, P. Ponka, D. Vyoral, 1996, Blood.

Deferiprone: greater efficacy at depleting myocardial than hepatic iron?

D. Richardson, 2002, The Lancet.

“Iron mining” to inhibit tumor growth

D. Richardson, D. Lovejoy, 2006 .

A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC

D. Richardson, N. Seebacher, P. Jansson, 2016, Cell Death & Disease.

Meeting the Challenge 2: Identification of Potential Chemical Probes for Parkinson's Disease from Ligusticum chuanxiong Hort Using Cytological Profiling.

D. Richardson, S. Wood, R. Quinn, 2022, ACS chemical neuroscience.

Examination of the distribution of the transferrin homologue, melanotransferrin (tumour antigen p97), in mouse and human.

D. Richardson, L. Dunn, E. Sekyere, 2005, Biochimica et biophysica acta.

The soluble form of the membrane-bound transferrin homologue, melanotransferrin, inefficiently donates iron to cells via nonspecific internalization and degradation of the protein.

D. Richardson, E. Sekyere, M. Food, 2002, European journal of biochemistry.

Iron chelators ICL670 and 311 inhibit HIV-1 transcription.

S. Nekhai, D. Richardson, V. Gordeuk, 2007, Virology.

Investigation of substituted 6-aminohexanoates as skin penetration enhancers.

D. Richardson, D. Kalinowski, J. Jampílek, 2012, Bioorganic & medicinal chemistry.

Development and validation of HPLC-DAD methods for the analysis of two novel iron chelators with potent anti-cancer activity.

J. Klimeš, D. Richardson, D. Kalinowski, 2007, Journal of pharmaceutical and biomedical analysis.

The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone.

D. Richardson, K. Milnes, 1997, Blood.

Proteolytic cleavage and truncation of NDRG1 in human prostate cancer cells, but not normal prostate epithelial cells

D. Richardson, S. Assinder, Q. Dong, 2013, Bioscience reports.

The Potent and Novel Thiosemicarbazone Chelators, Dp44mT and Bp44mT, Affect Crucial Thiol Systems Required for Ribonucleotide Reductase Activity

D. Richardson, Yu Yu, C. Hawkins, 2011 .

Cytotoxic iron chelators: characterization of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues

D. Richardson, P. Bernhardt, T. Chaston, 2003, JBIC Journal of Biological Inorganic Chemistry.

Iron catalysed assembly of an asymmetric mixed-ligand triple helicate.

D. Richardson, P. Bernhardt, P. Chin, 2004, Dalton transactions.

The Metastasis Suppressor, NDRG1, Attenuates Oncogenic TGF-β and NF-ĸB Signaling to Enhance Membrane E-Cadherin Expression in Pancreatic Cancer Cells.

D. Richardson, Z. Kovacevic, Alexander Richardson, 2019, Carcinogenesis.

Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity.

D. Richardson, D. Kalinowski, P. Bernhardt, 2009, Journal of medicinal chemistry.

The release of iron and transferrin from the human melanoma cell.

D. Richardson, E. Baker, 1991, Biochimica et biophysica acta.

Development of pyridyl thiosemicarbazones as highly potent agents for the treatment of malaria after oral administration.

D. Richardson, G. Birrell, C. Parkinson, 2019, The Journal of antimicrobial chemotherapy.

Synthesis and biological evaluation of substituted 2-benzoylpyridine thiosemicarbazones: novel structure-activity relationships underpinning their anti-proliferative and chelation efficacy.

D. Richardson, D. Kalinowski, Naresh Kumar, 2013, Bioorganic & medicinal chemistry letters.

Alkyl substituted 2'-benzoylpyridine thiosemicarbazone chelators with potent and selective anti-neoplastic activity: novel ligands that limit methemoglobin formation.

D. Richardson, D. Kalinowski, P. Bernhardt, 2013, Journal of medicinal chemistry.

Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy.

J. Polanski, D. Richardson, A. Ratuszna, 2012, Bioorganic & medicinal chemistry letters.

Halogenated 2'-benzoylpyridine thiosemicarbazone (XBpT) chelators with potent and selective anti-neoplastic activity: relationship to intracellular redox activity.

D. Richardson, D. Kalinowski, P. Bernhardt, 2011, Journal of medicinal chemistry.

Methemoglobin Formation by Triapine, Di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and Other Anticancer Thiosemicarbazones: Identification of Novel Thiosemicarbazones and Therapeutics That Prevent This Effect

D. Richardson, D. Kalinowski, P. Bernhardt, 2012, Molecular Pharmacology.

Iron uptake by melanoma cells from the soluble form of the transferrin homologue, melanotransferrin

D. Richardson, M. Food, 2002, Redox report : communications in free radical research.

The thiosemicarbazone, DpC, broadly synergizes with multiple anti-cancer therapeutics and demonstrates temperature- and energy-dependent uptake by tumor cells.

D. Richardson, P. Jansson, R. Afroz, 2022, Biochimica et biophysica acta. General subjects.

Nitrogen monoxide activates iron regulatory protein 1 RNA-binding activity by two possible mechanisms: effect on the [4Fe-4S] cluster and iron mobilization from cells.

D. Richardson, R. Watts, S. Wardrop, 2000, Biochemistry.

The anti-tumor agent, Dp44mT, promotes nuclear translocation of TFEB via inhibition of the AMPK-MTORC1 axis.

D. Richardson, S. Sahni, S. Krishan, 2020, Biochimica et biophysica acta. Molecular basis of disease.

PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice.

D. Richardson, J. Kwok, C. S. Wong, 2004, Biochimica et biophysica acta.

Beta-thalassaemia: emergence of new and improved iron chelators for treatment.

D. Richardson, Cynthia Wong, 2003, The international journal of biochemistry & cell biology.

Growth of human tumor cell lines in transferrin-free, low-iron medium

D. Richardson, J. Kovar, K. Kriegerbecková, 1995, In Vitro Cellular & Developmental Biology - Animal.

Making a case for albumin – a highly promising drug-delivery system.

D. Richardson, D. Kalinowski, S. Sahni, 2015, Future medicinal chemistry.

Identification of differential phosphorylation and sub-cellular localization of the metastasis suppressor, NDRG1.

D. Richardson, K. Park, D. Kalinowski, 2018, Biochimica et biophysica acta. Molecular basis of disease.

Endoplasmic reticulum protein 29 (ERp29): An emerging role in cancer.

Daohai Zhang, D. Richardson, 2011, The international journal of biochemistry & cell biology.

The metastasis suppressor NDRG1 down-regulates the epidermal growth factor receptor via a lysosomal mechanism by up-regulating mitogen-inducible gene 6

D. Richardson, Z. Kovacevic, Sharleen V. Menezes, 2019, The Journal of Biological Chemistry.

Two mechanisms of iron uptake from transferrin by melanoma cells. The effect of desferrioxamine and ferric ammonium citrate.

D. Richardson, E. Baker, 1992, The Journal of biological chemistry.

The uptake of inorganic iron complexes by human melanoma cells.

D. Richardson, E. Baker, 1991, Biochimica et biophysica acta.

Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2‐hydroxy‐1‐naphthylaldehyde using the hepatocyte in culture

D. Richardson, P. Ponka, S. Gross, 1992, Hepatology.

The good Samaritan glutathione-S-transferase P1: An evolving relationship in nitric oxide metabolism mediated by the direct interactions between multiple effector molecules

D. Richardson, Tiffany M Russell, 2022, Redox biology.

THE BIOLOGICAL CONSEQUENCES OF KAOLIN GEOPHAGIA

V. Rangari, D. Richardson, R. Ankumah, 2014 .

Competing pathways of iron chelation: Angiogenesis or anti‐tumor activity: Targeting different molecules to induce specific effects

D. Richardson, N. Le, 2004, International journal of cancer.

Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.

D. Richardson, D. Obando, P. Witting, 2010, Journal of medicinal chemistry.

Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells

D. Richardson, E. Noulsri, S. Fucharoen, 2009, American journal of hematology.

Investigating biological activity spectrum for novel quinoline analogues.

J. Polanski, D. Richardson, D. Kalinowski, 2007, Bioorganic & medicinal chemistry.

Development of a sensitive HPLC method to measure in vitro permeability of E- and Z-isomeric forms of thiosemicarbazones in Caco-2 monolayers.

S. Nekhai, D. Richardson, V. Gordeuk, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Changes in ferrous iron and glutathione promote ferroptosis and frailty in aging Caenorhabditis elegans

T. Speed, A. Bush, S. James, 2020, eLife.

Ferrous-glutathione coupling mediates ferroptosis and frailty in Caenorhabditis elegans

T. Speed, A. Bush, S. James, 2019, bioRxiv.

Pyridoxal isonicotinoyl hydrazone and analogues

D. Richardson, J. Webb, Lucia M. Wis Vitolo, 2005, Biology of Metals.

Redox cycling metals: Pedaling their roles in metabolism and their use in the development of novel therapeutics.

T. Ganz, D. Richardson, S. Toyokuni, 2016, Biochimica et biophysica acta.

The active role of vitamin C in mammalian iron metabolism: much more than just enhanced iron absorption!

D. Richardson, D. Lane, 2014, Free radical biology & medicine.

Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.

D. Richardson, D. Kalinowski, P. Bernhardt, 2008, Journal of medicinal chemistry.

Novel diaroylhydrazine ligands as iron chelators: coordination chemistry and biological activity

D. Richardson, P. Bernhardt, P. C. Sharpe, 2005, JBIC Journal of Biological Inorganic Chemistry.

Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.

D. Richardson, Yu Yu, D. Kalinowski, 2009, Journal of medicinal chemistry.

Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites.

D. Richardson, V. Gordeuk, M. Loyevsky, 2004, The international journal of biochemistry & cell biology.

Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc Down-Stream Regulated Gene 1: A New Strategy for the Treatment of Pancreatic Cancer

D. Richardson, Z. Kovacevic, D. Lovejoy, 2011, Molecular Pharmacology.

The medicinal chemistry of novel iron chelators for the treatment of cancer.

D. Richardson, Y. Suryo Rahmanto, Yu Yu, 2011, Current topics in medicinal chemistry.

The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer

D. Richardson, D. Kalinowski, 2005, Pharmacological Reviews.

Heterocyclic dithiocarbazate iron chelators: Fe coordination chemistry and biological activity.

D. Richardson, Jy D. Chartres, D. Kalinowski, 2012, Dalton transactions.

Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilise iron from reticulocytes in vitro.

D. Richardson, P. Ponka, J. T. Edward, 1994, Canadian journal of physiology and pharmacology.

Letter to the Editor: “Analysis of the Interaction of Dp44mT with Human Serum Albumin and Calf Thymus DNA Using Molecular Docking and Spectroscopic Techniques”

D. Richardson, D. Kalinowski, S. Sahni, 2016, International journal of molecular sciences.

Structural Variations and Formation Constants of First-Row Transition Metal Complexes of Biologically Active Aroylhydrazones

D. Richardson, P. Bernhardt, P. Chin, 2003 .

Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy

D. Richardson, P. Bernhardt, P. Chin, 2001, JBIC Journal of Biological Inorganic Chemistry.

Synthesis and biological evaluation of 2-benzoylpyridine thiosemicarbazones in a dimeric system: structure-activity relationship studies on their anti-proliferative and iron chelation efficacy.

D. Richardson, D. Kalinowski, Adeline Y Lukmantara, 2014, Journal of inorganic biochemistry.

Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo.

D. Richardson, D. Kalinowski, N. Seebacher, 2012, Journal of medicinal chemistry.

The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against Human Lung Tumor Xenografts and Molecular Mechanism of Action

D. Richardson, D. Kalinowski, Z. Kovacevic, 2013, Molecular Pharmacology.

Tuning the antiproliferative activity of biologically active iron chelators: characterization of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine hydrazone ligands

D. Richardson, G. Wilson, D. Kalinowski, 2007, JBIC Journal of Biological Inorganic Chemistry.

Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part I. Ionisation characteristics of the ligands and their relevance to biological properties

D. Richardson, G. Hefter, P. Wilairat, 1990 .

2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity.

D. Richardson, D. Kalinowski, P. Bernhardt, 2009, Journal of medicinal chemistry.

Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.

D. Richardson, Yu Yu, D. Kalinowski, 2007, Journal of medicinal chemistry.

Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity.

D. Richardson, D. Kalinowski, P. Bernhardt, 2006, Journal of medicinal chemistry.

Novel Mechanism of Cytotoxicity for the Selective Selenosemicarbazone, 2-Acetylpyridine 4,4-Dimethyl-3-selenosemicarbazone (Ap44mSe): Lysosomal Membrane Permeabilization.

D. Richardson, D. Kalinowski, S. Sahni, 2016, Journal of medicinal chemistry.

Structure-activity studies of 4-phenyl-substituted 2'-benzoylpyridine thiosemicarbazones with potent and selective anti-tumour activity.

D. Richardson, D. Kalinowski, Adeline Y Lukmantara, 2013, Organic & biomolecular chemistry.

Thiosemicarbazones: the new wave in cancer treatment.

D. Richardson, D. Kalinowski, P. Quach, 2009, Future medicinal chemistry.

Complexes of cytotoxic chelators from the dipyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues.

D. Richardson, J. Mattsson, P. Bernhardt, 2006, Inorganic chemistry.

Effect of the Piperazine Unit and Metal-Binding Site Position on the Solubility and Anti-Proliferative Activity of Ruthenium(II)- and Osmium(II)- Arene Complexes of Isomeric Indolo[3,2-c]quinoline—Piperazine Hybrids

D. Richardson, D. Kalinowski, V. Arion, 2014, Inorganic chemistry.

Complexes of gallium(III) and other metal ions and their potential in the treatment of neoplasia

D. Richardson, D. Lovejoy, 2000, Expert opinion on investigational drugs.

Identification of the di‐pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti‐tumour agents

D. Richardson, J. Greer, D. Lovejoy, 2003, British journal of pharmacology.

The role of iron in cell cycle progression and the proliferation of neoplastic cells.

D. Richardson, N. Le, 2002, Biochimica et biophysica acta.

Iron chelators as therapeutic agents for the treatment of cancer.

D. Richardson, 2002, Critical reviews in oncology/hematology.

Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease.

D. Richardson, P. Ponka, 1998, The Journal of laboratory and clinical medicine.

Potential of iron chelators as effective antiproliferative agents.

D. Richardson, 1997, Canadian journal of physiology and pharmacology.

Iron: a new target for pharmacological intervention in neurodegenerative diseases.

D. Richardson, Megan Whitnall, 2006, Seminars in pediatric neurology.

Iron chelators of the pyridoxal isonicotinoyl hydrazone class

D. Richardson, G. Hefter, P. M. May, 1989, Biology of Metals.

Partition coefficients of the iron(III) complexes of pyridoxal isonicotinoyl hydrazone and its analogs and the correlation to iron chelation efficacy

D. Richardson, P. Ponka, J. T. Edward, 1995, Biometals.

The controversial role of deferiprone in the treatment of thalassemia.

D. Richardson, 2001, The Journal of laboratory and clinical medicine.

The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents.

D. Richardson, P. Ponka, E. Tran, 1995, Blood.

Novel chelators for cancer treatment: where are we now?

D. Richardson, D. Kalinowski, A. Merlot, 2013, Antioxidants & redox signaling.

Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents.

D. Richardson, D. Kalinowski, P. Jansson, 2009, Biochimica et biophysica acta.

Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicity

D. Richardson, T. Chaston, 2003, American journal of hematology.

Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.

D. Richardson, E. Becker, 1999, The Journal of laboratory and clinical medicine.

The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.

D. Richardson, G Darnell, D R Richardson, 1999, Blood.

Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia.

D. Richardson, 1998, Leukemia & lymphoma.

Zinc(II)-Thiosemicarbazone Complexes Are Localized to the Lysosomal Compartment Where They Transmetallate with Copper Ions to Induce Cytotoxicity.

D. Richardson, D. Kalinowski, P. Bernhardt, 2016, Journal of medicinal chemistry.

Identification and characterization of thiosemicarbazones with antifungal and antitumor effects: cellular iron chelation mediating cytotoxic activity.

D. Richardson, V. Buchta, D. Kalinowski, 2008, Chemical research in toxicology.

Therapeutic potential of iron chelators in cancer therapy.

D. Richardson, 2002, Advances in experimental medicine and biology.

Exploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents.

D. Richardson, D. Kalinowski, S. Sahni, 2019, Current medicinal chemistry.

Siderocalin/Lcn2/NGAL/24p3 Does Not Drive Apoptosis Through Gentisic Acid Mediated Iron Withdrawal in Hematopoietic Cell Lines

R. Strong, C. Correnti, A. Bandaranayake, 2012, PloS one.

Synthesis, Characterization, and in Vitro Anticancer Activity of Copper and Zinc Bis(Thiosemicarbazone) Complexes.

D. Richardson, W. Lewis, K. Park, 2019, Inorganic chemistry.

Investigating the antiproliferative activity of quinoline-5,8-diones and styrylquinolinecarboxylic acids on tumor cell lines.

J. Polanski, D. Richardson, D. Kalinowski, 2007, Bioorganic & medicinal chemistry letters.

Investigating the activity of 2-substituted alkyl-6-(2,5-dioxopyrrolidin-1-yl)hexanoates as skin penetration enhancers.

D. Richardson, D. Kalinowski, J. Jampílek, 2010, Bioorganic & medicinal chemistry.

Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes.

D. Richardson, P. Ponka, U. Brunk, 2011, Cancer research.

Designing Tailored Thiosemicarbazones with Bespoke Properties: The Styrene Moiety Imparts Potent Activity, Inhibits Heme Center Oxidation, and Results in a Novel "Stealth Zinc(II) Complex".

D. Richardson, P. Bernhardt, Buşra Kaya, 2023, Journal of medicinal chemistry.

The biologically active iron chelators 2-pyridylcarboxaldehyde isonicotinoylhydrazone, 2-pyridylcarboxaldehyde benzoylhydrazone monohydrate and 2-furaldehyde isonicotinoylhydrazone.

D. Richardson, P. Bernhardt, E. Becker, 1999, Acta crystallographica. Section C, Crystal structure communications.

Design, synthesis, and characterization of new iron chelators with anti-proliferative activity: structure-activity relationships of novel thiohydrazone analogues.

D. Richardson, D. Kalinowski, P. Bernhardt, 2007, Journal of medicinal chemistry.

Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury.

D. Richardson, K. Vávrová, D. Kalinowski, 2010, Chemical research in toxicology.

Metals and metastasis: Exploiting the role of metals in cancer metastasis to develop novel anti‐metastatic agents

D. Richardson, Z. Kovacevic, Sharleen V. Menezes, 2017, Pharmacological research.

Duodenal Cytochrome b (DCYTB) in Iron Metabolism: An Update on Function and Regulation

D. Richardson, S. Sahni, D. Lane, 2015, Nutrients.

Pharmacological targeting of mitochondria in cancer stem cells: An ancient organelle at the crossroad of novel anti‐cancer therapies

D. Richardson, R. Veselska, P. Jansson, 2019, Pharmacological research.

The Anticancer Agent, Di-2-Pyridylketone 4,4-Dimethyl-3-Thiosemicarbazone (Dp44mT), Up-Regulates the AMPK-Dependent Energy Homeostasis Pathway in Cancer Cells.

D. Richardson, S. Sahni, S. Krishan, 2016, Biochimica et biophysica acta.

Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents

D. Richardson, D. Kalinowski, J. Chládek, 2015, Oncotarget.

Quantitative Analysis of the Anti-Proliferative Activity of Combinations of Selected Iron-Chelating Agents and Clinically Used Anti-Neoplastic Drugs

D. Richardson, D. Kalinowski, Eliška Potůčková, 2014, PloS one.

The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity.

D. Richardson, D. Kalinowski, P. Mladěnka, 2009, Chemical research in toxicology.

Protection against Hydrogen Peroxide-Mediated Cytotoxicity in Friedreich's Ataxia Fibroblasts Using Novel Iron Chelators of the 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone Class

D. Richardson, D. Kalinowski, C. Lim, 2008, Molecular Pharmacology.

A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics

D. Richardson, P. Ponka, Des R Richardson, 2006, Proceedings of the National Academy of Sciences.

Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: The effect of transferrin concentration, chelators, and metabolic probes on transferrin and iron uptake

D. Richardson, E. Baker, 1994, Journal of cellular physiology.

The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.

D. Richardson, P. Ponka, E. Baker, 1994, Cancer research.

Novel multifunctional iron chelators of the aroyl nicotinoyl hydrazone class that markedly enhance cellular NAD+/NADH ratios

S. Egan, N. Braidy, D. Richardson, 2020, British journal of pharmacology.

Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: application to a pilot pharmacokinetic study in rats.

J. Klimeš, M. Nobilis, D. Richardson, 2014, Biomedical chromatography : BMC.

Potent Antimycobacterial Activity of the Pyridoxal Isonicotinoyl Hydrazone Analog 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone: A Lipophilic Transport Vehicle for Isonicotinic Acid Hydrazide

V. Sintchenko, D. Richardson, D. Kalinowski, 2014, Molecular Pharmacology.

Potent Anti-Mycobacterial Activity of the Pyridoxal Isonicotinoyl Hydrazone Analogue , 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone : A Lipophilic Transport Vehicle for Isonicotinic Acid Hydrazide

Sintchenko, D. Richardson, D. Kalinowski, 2013 .

Development of an LC–MS/MS method for analysis of interconvertible Z/E isomers of the novel anticancer agent, Bp4eT

J. Klimeš, D. Richardson, D. Kalinowski, 2010, Analytical and bioanalytical chemistry.

HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and Dp44mT) in plasma and their application to in vitro plasma stability of these agents.

J. Klimeš, D. Richardson, D. Kalinowski, 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Novel Chelators for Central Nervous System Disorders That Involve Alterations in the Metabolism of Iron and Other Metal Ions

D. Richardson, 2004, Annals of the New York Academy of Sciences.

Four cytotoxic N4-substituted thiosemicarbazones derived from 2-hydroxynaphthalene-1-carboxaldehyde.

D. Richardson, P. Bernhardt, D. Lovejoy, 2003, Acta crystallographica. Section C, Crystal structure communications.

Synthetic and natural products as iron chelators.

D. Richardson, D. Kalinowski, P. Bernhardt, 2011, Current topics in medicinal chemistry.

Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity.

D. Richardson, P. Bernhardt, P. C. Sharpe, 2007, Dalton transactions.

Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-tumour activity

D. Richardson, P. Bernhardt, 1999, JBIC Journal of Biological Inorganic Chemistry.

Targeting cancer by binding iron: Dissecting cellular signaling pathways

D. Richardson, D. Kalinowski, Z. Kovacevic, 2015, Oncotarget.

Expanding horizons in iron chelation and the treatment of cancer: role of iron in the regulation of ER stress and the epithelial-mesenchymal transition.

D. Richardson, D. Kalinowski, N. Shafie, 2014, Biochimica et biophysica acta.

The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the "Triad of Death" in cancer by Di-2-pyridylketone thiosemicarbazones.

D. Richardson, D. Kalinowski, S. Sahni, 2015, Pharmacological research.

A novel class of thiosemicarbazones show multi-functional activity for the treatment of Alzheimer's disease.

D. Hibbs, D. Richardson, D. Kalinowski, 2017, European journal of medicinal chemistry.

Anti-plasmodial activity of aroylhydrazone and thiosemicarbazone iron chelators: effect on erythrocyte membrane integrity, parasite development and the intracellular labile iron pool.

D. Richardson, D. Kalinowski, J. Kwagyan, 2013, Journal of inorganic biochemistry.

Melatonin-Based Therapeutics for Atherosclerotic Lesions and Beyond: Focusing on Macrophage Mitophagy.

D. Klionsky, D. Mcclements, D. Richardson, 2022, Pharmacological research.

Gene of the month: Interleukin 6 (IL-6)

D. Richardson, D. Morris, M. Pourgholami, 2014, Journal of Clinical Pathology.

The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: an EPR study.

D. Richardson, C. Hawkins, P. Jansson, 2010, Journal of inorganic biochemistry.

Tuning Cell Cycle Regulation with an Iron Key

D. Richardson, Yu Yu, Z. Kovacevic, 2007, Cell cycle.

Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation.

D. Richardson, Des R Richardson, Nghia T V Le, 2004, Blood.

Identification of differential anti-neoplastic activity of copper bis(thiosemicarbazones) that is mediated by intracellular reactive oxygen species generation and lysosomal membrane permeabilization.

D. Richardson, D. Kalinowski, P. Jansson, 2015, Journal of inorganic biochemistry.

Potentiating the cellular targeting and anti-tumor activity of Dp44mT via binding to human serum albumin: two saturable mechanisms of Dp44mT uptake by cells

D. Hibbs, M. Doddareddy, D. Richardson, 2015, Oncotarget.

Di-2-pyridylketone 4,4-Dimethyl-3-thiosemicarbazone (Dp44mT) Overcomes Multidrug Resistance by a Novel Mechanism Involving the Hijacking of Lysosomal P-Glycoprotein (Pgp)*

D. Richardson, S. Sahni, N. Seebacher, 2015, The Journal of Biological Chemistry.

Iron chelators for the treatment of cancer.

D. Richardson, F. Saletta, Y. Suryo Rahmanto, 2012, Current medicinal chemistry.

Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti‐tumour efficacy

D. Richardson, Y. Yu, Y. S. Rahmanto, 2012, British journal of pharmacology.

Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types

D. Richardson, Z. Kovacevic, R. S. Moussa, 2015, Oncotarget.

Molecular Pharmacology of ABCG2 and Its Role in Chemoresistance

D. Richardson, P. Jansson, Alexandra E. Stacy, 2013, Molecular Pharmacology.

Targeting the Metastasis Suppressor, N-Myc Downstream Regulated Gene-1, with Novel Di-2-Pyridylketone Thiosemicarbazones: Suppression of Tumor Cell Migration and Cell-Collagen Adhesion by Inhibiting Focal Adhesion Kinase/Paxillin Signaling

M. Zheng, D. Richardson, Xiongzhi Wangpu, 2016, Molecular Pharmacology.

Targeting the Metastasis Suppressor, NDRG1, Using Novel Iron Chelators: Regulation of Stress Fiber-Mediated Tumor Cell Migration via Modulation of the ROCK1/pMLC2 Signaling Pathway

M. Zheng, Daohai Zhang, D. Richardson, 2013, Molecular Pharmacology.

Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol

D. Richardson, P. Ponka, A. Sheftel, 2010, Proceedings of the National Academy of Sciences.

The mechanism of nitrogen monoxide (NO)-mediated iron mobilization from cells. NO intercepts iron before incorporation into ferritin and indirectly mobilizes iron from ferritin in a glutathione-dependent manner.

D. Richardson, R. Watts, 2002, European journal of biochemistry.

The iron metabolism of neoplastic cells: alterations that facilitate proliferation?

D. Richardson, J. Kwok, 2002, Critical reviews in oncology/hematology.

Role of ceruloplasmin and ascorbate in cellular iron release.

D. Richardson, 1999, The Journal of laboratory and clinical medicine.

A novel iron uptake mechanism mediated by GPI‐anchored human p97.

W. Jefferies, D. Richardson, P. Ponka, 1995, The EMBO journal.

The melanoma tumor antigen, melanotransferrin (p97): a 25-year hallmark – from iron metabolism to tumorigenesis

D. Richardson, L. Dunn, Y. S. Rahmanto, 2007, Oncogene.

Melanotransferrin: search for a function.

D. Richardson, Y. Suryo Rahmanto, Yu Yu, 2012, Biochimica et biophysica acta.

Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling.

D. Richardson, D. Kalinowski, A. M. Merlot, 2016, Biochimica et biophysica acta.

ATP7A is a novel target of retinoic acid receptor β2 in neuroblastoma cells

D. Richardson, M. Haber, M. Norris, 2009, British Journal of Cancer.

The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells.

D. Richardson, P. Ponka, 1997, Biochimica et biophysica acta.

The translational regulator eIF3a: the tricky eIF3 subunit!

D. Richardson, F. Saletta, Y. Suryo Rahmanto, 2010, Biochimica et biophysica acta.

Antioxidant Defense Mechanisms and its Dysfunctional Regulation in the Mitochondrial Disease, Friedreich's Ataxia.

D. Richardson, M. Huang, K. C. Park, 2020, Free radical biology & medicine.

Targeting Oncogenic Nuclear Factor Kappa B Signaling with Redox-Active Agents for Cancer Treatment.

D. Richardson, Z. Kovacevic, L. Fouani, 2017, Antioxidants & redox signaling.

Treatment of Dilated Cardiomyopathy in a Mouse Model of Friedreich's Ataxia using N-acetylcysteine and Identification of Alterations in MicroRNA Expression that Could be Involved in its Pathogenesis.

D. Richardson, S. Chiang, M. L. Huang, 2020, Pharmacological research.

Proteomic analysis of hearts from frataxin knockout mice: Marked rearrangement of energy metabolism, a response to cellular stress and altered expression of proteins involved in cell structure, motility and metabolism

D. Richardson, M. Kashem, D. Vyoral, 2008, Proteomics.

Ferritinophagy and α-Synuclein: Pharmacological Targeting of Autophagy to Restore Iron Regulation in Parkinson’s Disease

V. Uversky, A. Roberts, D. Richardson, 2022, International journal of molecular sciences.

The Role of the Antioxidant Response in Mitochondrial Dysfunction in Degenerative Diseases: Cross-Talk between Antioxidant Defense, Autophagy, and Apoptosis

D. Richardson, D. Kalinowski, S. Sahni, 2019, Oxidative medicine and cellular longevity.

The c-MET oncoprotein: Function, mechanisms of degradation and its targeting by novel anti-cancer agents.

D. Richardson, K. Park, 2020, Biochimica et biophysica acta. General subjects.

The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms

D. Richardson, D. Kalinowski, G. C. Chan, 2016, Journal of Hematology & Oncology.

Calcium channels and iron metabolism: A redox catastrophe in Parkinson's disease and an innovative path to novel therapies?

Alan Wee-Chung Liew, D. Richardson, Linlin Ma, 2021, Redox biology.

Ironing out the role of the cyclin‐dependent kinase inhibitor, p21 in cancer: Novel iron chelating agents to target p21 expression and activity

D. Richardson, K. Park, Z. Kovacevic, 2019, Free radical biology & medicine.

Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy.

D. Richardson, K. Park, D. Kalinowski, 2012, Biochimica et biophysica acta.

The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer.

D. Richardson, Z. Kovacevic, Des R Richardson, 2006, Carcinogenesis.

The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity

D. Richardson, M. G. Azad, Jason Chekmarev, 2021, Cells.

Ascorbate and Tumor Cell Iron Metabolism: The Evolving Story and its Link to Pathology.

D. Richardson, D. Kalinowski, P. Jansson, 2020, Antioxidants & redox signaling.

Iron and neoplasia: serum transferrin receptor and ferritin in prostate cancer.

D. Richardson, 2004, The Journal of laboratory and clinical medicine.

The molecular effect of metastasis suppressors on Src signaling and tumorigenesis: new therapeutic targets

M. Zheng, D. Richardson, Zhihai Peng, 2015, Oncotarget.

Pharmacological targeting and the diverse functions of the metastasis suppressor, NDRG1, in cancer.

D. Richardson, K. Park, Z. Kovacevic, 2020, Free radical biology & medicine.

Induction of Nramp2 in activated mouse macrophages is dissociated from regulation of the Nramp1, classical inflammatory genes, and genes involved in iron metabolism

D. Hume, T. Ravasi, C. Wells, 2002, Journal of leukocyte biology.

Novel Thiosemicarbazones Sensitize Pediatric Solid Tumor Cell-Types to Conventional Chemotherapeutics through Multiple Molecular Mechanisms

D. Richardson, J. Štěrba, J. Neradil, 2020, Cancers.

Frataxin and the molecular mechanism of mitochondrial iron-loading in Friedreich's ataxia.

D. Richardson, D. Kalinowski, S. Sahni, 2016, Clinical science.

compared to molecules involved in iron metabolism and hemoglobinization expression in Friend cells: characterization of frataxin expression Erythroid differentiation and protoporphyrin IX down-regulate frataxin

D. Richardson, P. Ponka, J. Greer, 2013 .

Erythroid differentiation and protoporphyrin IX down-regulate frataxin expression in Friend cells: characterization of frataxin expression compared to molecules involved in iron metabolism and hemoglobinization.

D. Richardson, P. Ponka, J. Greer, 2002, Blood.

Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation.

D. Richardson, N. Le, 2003, Carcinogenesis.

The Role of Extracellular Proteases in Tumor Progression and the Development of Innovative Metal Ion Chelators That Inhibit Their Activity

D. Richardson, K. Park, M. Dharmasivam, 2020, International journal of molecular sciences.

Turning the gun on cancer: Utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistance.

D. Richardson, N. Seebacher, P. Jansson, 2016, Free radical biology & medicine.

Pharmacological Targeting of the Integrated Protein Kinase B, Phosphatase and Tensin Homolog Deleted on Chromosome 10, and Transforming Growth Factor-β Pathways in Prostate Cancer

D. Richardson, S. Assinder, H. Mångs, 2009, Molecular Pharmacology.

The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer.

D. Richardson, S. Assinder, Z. Kovacevic, 2009, The Biochemical journal.

Can ferritin provide iron for hemoglobin synthesis?

D. Richardson, P. Ponka, 1997, Blood.

disease Iron trafficking in the mitochondrion: novel pathways revealed by

D. Richardson, P. Ponka, I. Napier, 2013 .

Iron trafficking in the mitochondrion: novel pathways revealed by disease.

D. Richardson, P. Ponka, Des R Richardson, 2005, Blood.

Mechanism of the induction of endoplasmic reticulum stress by the anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT): Activation of PERK/eIF2α, IRE1α, ATF6 and calmodulin kinase.

D. Richardson, Yu Yu, D. Kalinowski, 2016, Biochemical pharmacology.

An Innovative Non-Hormonal Strategy Targeting Redox Active Metals to Down-Regulate Estrogen-, Progesterone-, Androgen- and Prolactin-Receptors in Breast Cancer

D. Richardson, Robin L. Anderson, Dinny Graham, 2023, bioRxiv.

mechanismsofaction ofDFO in neoplasticcellsand becauserecentstudies

D. Richardson, P. Ponka, E. Baker, 2006 .

Iron-binding drugs targeted to lysosomes: a potential strategy to treat inflammatory lung disorders

D. Richardson, H. L. Persson, H. Persson, 2005, Expert opinion on investigational drugs.

Uptake by the Human Malignant Melanoma Cell

D. Richardson, P. Ponka, E. Baker, 1994 .

The role of the NDRG1 in the pathogenesis and treatment of breast cancer.

D. Richardson, Xiao Zhao, Xiao Zhao, 2023, Biochimica et biophysica acta. Reviews on cancer.

Copper and conquer: copper complexes of di-2-pyridylketone thiosemicarbazones as novel anti-cancer therapeutics.

D. Richardson, K. Park, D. Kalinowski, 2016, Metallomics : integrated biometal science.

Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding

D. Richardson, K. Park, Z. Kovacevic, 2019, The Journal of Biological Chemistry.

The Progression of Cardiomyopathy in the Mitochondrial Disease, Friedreich’s Ataxia

D. Richardson, M. Huang, S. Sivagurunathan, 2014 .

Antioxidants Inhibit Indoleamine 2,3-Dioxygenase in IFN-γ-Activated Human Macrophages: Posttranslational Regulation by Pyrrolidine Dithiocarbamate1

D. Richardson, R. Stocker, N. Hunt, 2001, The Journal of Immunology.

CD63 is regulated by iron via the IRE-IRP system and is important for ferritin secretion by extracellular vesicles

I. Yanatori, D. Richardson, S. Toyokuni, 2021, Blood.

The effect of redox-related species of nitrogen monoxide on transferrin and iron uptake and cellular proliferation of erythroleukemia (K562) cells.

D. Richardson, P. Ponka, E. Nagy, 1995, Blood.

E6AP Promotes a Metastatic Phenotype in Prostate Cancer

S. Fox, E. Gallo, L. Horvath, 2019, iScience.

Novel Thiosemicarbazones Inhibit Lysine-Rich Carcinoembryonic Antigen–Related Cell Adhesion Molecule 1 (CEACAM1) Coisolated (LYRIC) and the LYRIC-Induced Epithelial-Mesenchymal Transition via Upregulation of N-Myc Downstream-Regulated Gene 1 (NDRG1)

D. Richardson, D. Kalinowski, Xiaozhi Zhang, 2017, Molecular Pharmacology.

Novel Thiosemicarbazones Inhibit Lysine-Rich CEACAM 1 Co-isolated ( LYRIC ) and the LYRIC-Induced Epithelial-Mesenchymal Transition via Up-Regulation of N-Myc Downstream-Regulated Gene 1 ( NDRG 1 )

D. Richardson, D. Kalinowski, Xiaozhi Zhang, 2017 .

NDRG1 as a molecular target to inhibit the epithelial-mesenchymal transition: the case for developing inhibitors of metastasis.

D. Richardson, S. Sahni, S. Krishan, 2014, Future medicinal chemistry.

Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors.

M. Zheng, Daohai Zhang, D. Richardson, 2013, Carcinogenesis.

N-myc Downstream Regulated 1 (NDRG1) Is Regulated by Eukaryotic Initiation Factor 3a (eIF3a) during Cellular Stress Caused by Iron Depletion

D. Richardson, F. Saletta, Z. Kovacevic, 2013, PloS one.

The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways.

D. Richardson, Z. Kovacevic, S. Sivagurunathan, 2013, Antioxidants & redox signaling.

PGRMC1 regulation by phosphorylation: potential new insights in controlling biological activity!

D. Richardson, M. Cahill, J. Jazayeri, 2016, Oncotarget.

Hepcidin Bound to α2-Macroglobulin Reduces Ferroportin-1 Expression and Enhances Its Activity at Reducing Serum Iron Levels

M. Sari, D. Richardson, Y. Suryo Rahmanto, 2013, The Journal of Biological Chemistry.

Iron Levels Enhances Its Activity at Reducing Serum Reduces Ferroportin-1 Expression and-Macroglobulin 2 α Hepcidin Bound to Metabolism :

M. Sari, D. Richardson, P. Ponka, 2013 .

Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process.

D. Richardson, 1997, Biochimica et biophysica acta.

Tumor-induced neoangiogenesis and receptor tyrosine kinases - Mechanisms and strategies for acquired resistance.

D. Richardson, D. Kalinowski, Z. Kovacevic, 2019, Biochimica et biophysica acta. General subjects.

Tumor stressors induce two mechanisms of intracellular P-glycoprotein–mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones

D. Richardson, K. Park, S. Sahni, 2018, The Journal of Biological Chemistry.

Receptor Recognition and Lysosomal Targeting to Enhance Cytotoxicity of Novel Anti-Cancer Agents that Bind Iron and Copper

D. Richardson, A. Merlot, 2014 .

Membrane Transport and Intracellular Sequestration of Novel Thiosemicarbazone Chelators for the Treatment of Cancer

D. Richardson, D. Kalinowski, A. Merlot, 2010, Molecular Pharmacology.

The metastasis suppressor, NDRG1, inhibits “stemness” of colorectal cancer via down-regulation of nuclear β-catenin and CD44

M. Zheng, D. Richardson, Jingkun Zhao, 2015, Oncotarget.

The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis.

D. Richardson, Y. Suryo Rahmanto, L. Dunn, 2006, Carcinogenesis.

AMP kinase (PRKAA1)

D. Richardson, S. Sahni, S. Krishan, 2014, Journal of Clinical Pathology.

The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1

M. Zheng, D. Richardson, D. Kalinowski, 2015, Oncotarget.

The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich’s ataxia

D. Richardson, Y. Suryo Rahmanto, P. Ponka, 2010, Journal of Molecular Medicine.

Iron uptake and metabolism in the new millennium.

D. Richardson, Y. Suryo Rahmanto, L. Dunn, 2007, Trends in cell biology.

The emerging role of progesterone receptor membrane component 1 (PGRMC1) in cancer biology.

D. Richardson, S. Toyokuni, M. Cahill, 2016, Biochimica et biophysica acta.

The nitric oxide-iron interplay in mammalian cells: transport and storage of dinitrosyl iron complexes.

D. Richardson, H. Lok, 2008, Biochimica et biophysica acta.

DNICs and intracellular iron: nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-mediated glutathione efflux via MRP1

D. Richardson, 2007 .

Coupling of the polyamine and iron metabolism pathways in the regulation of proliferation: Mechanistic links to alterations in key polyamine biosynthetic and catabolic enzymes.

D. Richardson, Y. Suryo Rahmanto, R. Casero, 2018, Biochimica et biophysica acta. Molecular basis of disease.

Regulation of autophagy and apoptosis by Dp44mT-mediated activation of AMPK in pancreatic cancer cells.

D. Richardson, S. Sahni, P. Jansson, 2020, Biochimica et biophysica acta. Molecular basis of disease.

Novel Thiosemicarbazones Regulate the Signal Transducer and Activator of Transcription 3 (STAT3) Pathway: Inhibition of Constitutive and Interleukin 6–Induced Activation by Iron Depletion

D. Richardson, D. Kalinowski, S. Sahni, 2015, Molecular Pharmacology.

Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression.

D. Richardson, J. Phang, Dong Fu, 2007, Blood.

Mitochondrial dysfunction in the neuro-degenerative and cardio-degenerative disease, Friedreich's ataxia

D. Richardson, D. Kalinowski, P. Jansson, 2017, Neurochemistry International.

Mitochondrial mayhem: the mitochondrion as a modulator of iron metabolism and its role in disease.

D. Richardson, D. Lane, M. Huang, 2011, Antioxidants & redox signaling.

Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant

D. Richardson, P. Ponka, M. Huang, 2009, Proceedings of the National Academy of Sciences.

Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies

I. Yanatori, D. Richardson, R. Quinn, 2021, Redox biology.

Cellular iron uptake, trafficking and metabolism: Key molecules and mechanisms and their roles in disease.

D. Richardson, D. Kalinowski, S. Sahni, 2015, Biochimica et biophysica acta.

Fixing frataxin: ‘ironing out’ the metabolic defect in Friedreich's ataxia

D. Richardson, D. Lane, A. Anzovino, 2014, British journal of pharmacology.

Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer.

D. Richardson, 2005, Current medicinal chemistry.

The role of the membrane-bound tumour antigen, melanotransferrin (p97), in iron uptake by the human malignant melanoma cell.

D. Richardson, 2000, European journal of biochemistry.

Biochemistry of cardiomyopathy in the mitochondrial disease Friedreich's ataxia.

D. Richardson, D. Lane, M. Huang, 2013, The Biochemical journal.

The double‐edged nature of using genetic databases: melanotransferrin genes and transcripts

D. Richardson, L. Dunn, E. Sekyere, 2003, FEBS letters.

Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators.

D. Richardson, D. Lovejoy, Des R. Richardson, 2003, Current medicinal chemistry.

Molecular Pharmacology of the Interaction of Anthracyclines with Iron

D. Richardson, H. L. Persson, D R Richardson, 2005, Molecular Pharmacology.

Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells

D. Richardson, S. Assinder, Z. Chen, 2013, British Journal of Cancer.

The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity

D. Richardson, J. Kwok, 2000, Redox report : communications in free radical research.

Mechanisms of impaired mitochondrial homeostasis and NAD+ metabolism in a model of mitochondrial heart disease exhibiting redox active iron accumulation

N. Braidy, D. Richardson, S. Lal, 2021, Redox biology.

Non‐thermal plasma induces a stress response in mesothelioma cells resulting in increased endocytosis, lysosome biogenesis and autophagy

M. Mizuno, M. Hori, D. Richardson, 2017, Free radical biology & medicine.

The mechanistic role of chemically diverse metal ions in the induction of autophagy

D. Richardson, S. Sahni, P. Jansson, 2017, Pharmacological research.

The Anticancer Agent Di-2-pyridylketone 4,4-Dimethyl-3-thiosemicarbazone (Dp44mT) Overcomes Prosurvival Autophagy by Two Mechanisms

D. Richardson, P. Jansson, Elaine Gutierrez, 2014, The Journal of Biological Chemistry.

Endoplasmic reticulum protein 29 regulates epithelial cell integrity during the mesenchymal–epithelial transition in breast cancer cells

D. Richardson, D. Zhang, Y. K. Lee, 2013, Oncogene.

The Metastasis Suppressor, N-myc Downstream-regulated Gene 1 (NDRG1), Inhibits Stress-induced Autophagy in Cancer Cells

D. Richardson, D. Kalinowski, S. Sahni, 2014, The Journal of Biological Chemistry.

The iron-regulated metastasis suppressor, Ndrg-1: identification of novel molecular targets.

D. Richardson, Z. Kovacevic, Dong Fu, 2008, Biochimica et biophysica acta.

Transcriptional regulation of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by the chelator, Dp44mT.

D. Richardson, Z. Kovacevic, D. Lane, 2017, Biochimica et biophysica acta. General subjects.

Effects of nitrogen monoxide and carbon monoxide on molecular and cellular iron metabolism: mirror-image effector molecules that target iron.

D. Richardson, P. Ponka, R. Watts, 2003, The Biochemical journal.

Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling

D. Richardson, S. Sahni, Z. Kovacevic, 2017, The Journal of Biological Chemistry.

Chelators at the Cancer Coalface: Desferrioxamine to Triapine and Beyond

D. Richardson, Yu Yu, D. Kalinowski, 2006, Clinical Cancer Research.

The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1.

D. Richardson, S. Liang, D R Richardson, 2003, Carcinogenesis.

Glutathione S-transferase and MRP1 form an integrated system involved in the storage and transport of dinitrosyl-dithiolato iron complexes in cells.

D. Richardson, D. Kalinowski, S. Sahni, 2014, Free radical biology & medicine.

NDRG1 suppresses basal and hypoxia-induced autophagy at both the initiation and degradation stages and sensitizes pancreatic cancer cells to lysosomal membrane permeabilization.

D. Richardson, K. Park, S. Sahni, 2020, Biochimica et biophysica acta. General subjects.

Targeting Wnt/tenascin C-mediated cross talk between pancreatic cancer cells and stellate cells via activation of the metastasis suppressor NDRG1

D. Richardson, M. Apte, S. Sahni, 2022, The Journal of biological chemistry.

Breaking the cycle: Targeting of NDRG1 to inhibit bi‐directional oncogenic cross‐talk between pancreatic cancer and stroma

M. Pajic, D. Richardson, K. Park, 2021, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

The biochemical and molecular mechanisms involved in the role of micro-tumor environment stress in development of drug resistance.

D. Richardson, P. Jansson, Lina Al-Akra, 2019, Biochimica et biophysica acta. General subjects.

Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo

D. Richardson, M. Muller, K. Vávrová, 2015 .

Differential effects on cellular iron metabolism of the physiologically relevant diatomic effector molecules, NO and CO, that bind iron.

D. Richardson, R. Watts, 2004, Biochimica et biophysica acta.

Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity.

D. Richardson, J. Kwok, 2002, Molecular pharmacology.

The effect of intracellular iron concentration and nitrogen monoxide on Nramp2 expression and non-transferrin-bound iron uptake.

D. Richardson, S. Wardrop, 1999, European journal of biochemistry.

29 - Effects of Nitrogen Monoxide on Cellular Iron Metabolism

D. Richardson, P. Ponka, 1996 .

Nitric Oxide Storage and Transport in Cells Are Mediated by Glutathione S-Transferase P1-1 and Multidrug Resistance Protein 1 via Dinitrosyl Iron Complexes*

D. Richardson, A. Townsend, D. Kalinowski, 2011, The Journal of Biological Chemistry.

Can we target the α2-macroglobulin-hepcidin interaction to treat pathologic hypoferremia?

D. Richardson, D. Lane, 2014, Future medicinal chemistry.

Iron Export through the Transporter Ferroportin 1 Is Modulated by the Iron Chaperone PCBP2*

I. Yanatori, D. Richardson, F. Kishi, 2016, The Journal of Biological Chemistry.

Biochemical and spectroscopic studies of human melanotransferrin (MTf): electron-paramagnetic resonance evidence for a difference between the iron-binding site of MTf and other transferrins.

T. Bui, A. Drake, D. Richardson, 2008, The international journal of biochemistry & cell biology.

Iron Chelation by Clinically Relevant Anthracyclines: Alteration in Expression of Iron-Regulated Genes and Atypical Changes in Intracellular Iron Distribution and Trafficking

D. Richardson, R. Sutak, X. Xu, 2008, Molecular Pharmacology.

During mitosis ZEB1 switches from being a chromatin-bound epithelial gene repressor, to become a microtubule-associated protein.

D. Richardson, Z. Kovacevic, P. Jansson, 2020, Biochimica et biophysica acta. Molecular cell research.

Crusade for iron: iron uptake in unicellular eukaryotes and its significance for virulence.

D. Richardson, J. Tachezy, E. Lesuisse, 2008, Trends in microbiology.

Melanotransferrin Functions as a Pro-Oncogenic WNT Agonist: A Yin-Yang Relationship in Melanoma with the WNT Antagonist and Metastasis Suppressor, NDRG1

J. Wilmott, X. Zhao, D. Richardson, 2023, bioRxiv.

Proton transfer and ferredoxin I: the secrets of redox-driven proton transfer between solvent and a buried iron-sulphur cluster (3Fe-4S)

D. Richardson, 2001, Redox report : communications in free radical research.

‘proton wires’ composed of chains of water molecules and protonatable amino-acid side chains are important in mediating proton transfer in cytochrome oxidase and the light-driven proton pump bacteriorhodopsin.1–3 In contrast to the tunneling of protons through water

D. Richardson, 2001 .

Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron.

D. Richardson, P. Ponka, E. Becker, 2001, Biochimica et biophysica acta.

IRON METABOLISM AND AUTOPHAGY: A POORLY EXPLORED RELATIONSHIP THAT HAS IMPORTANT CONSEQUENCES FOR HEALTH AND DISEASE

D. Richardson, S. Sahni, P. Jansson, 2015, Nagoya journal of medical science.

Acireductone dioxygenase 1 (ADI1) is regulated by cellular iron by a mechanism involving the iron chaperone, PCBP1, with PCBP2 acting as a potential co-chaperone.

D. Richardson, R. Sutak, P. Jansson, 2020, Biochimica et biophysica acta. Molecular basis of disease.

Gene of the month: BECN1

D. Richardson, S. Sahni, P. Jansson, 2014, Journal of Clinical Pathology.

Friedreich’s ataxia: iron chelators that target the mitochondrion as a therapeutic strategy?

D. Richardson, 2003, Expert opinion on investigational drugs.

The Relationship of Glutathione-S-Transferase and Multi-Drug Resistance-Related Protein 1 in Nitric Oxide (NO) Transport and Storage

D. Richardson, M. G. Azad, Tiffany M Russell, 2021, Molecules.

Cellular Iron Depletion and the Mechanisms Involved in the Iron-dependent Regulation of the Growth Arrest and DNA Damage Family of Genes*

D. Richardson, F. Saletta, Federica Saletta, 2011, The Journal of Biological Chemistry.

Hepcidin, show some self-control! How the hormone of iron metabolism regulates its own expression.

D. Richardson, D. Lane, M. Huang, 2013, The Biochemical journal.

Novel chelators based on adamantane-derived semicarbazones and hydrazones that target multiple hallmarks of Alzheimer's disease.

N. Braidy, D. Richardson, D. Kalinowski, 2018, Dalton transactions.

Interferon-gamma and lipopolysaccharide regulate the expression of Nramp2 and increase the uptake of iron from low relative molecular mass complexes by macrophages.

D. Richardson, S. Wardrop, 2000, European journal of biochemistry.

Adenosine Monophosphate–Activated Kinase and Its Key Role in Catabolism: Structure, Regulation, Biological Activity, and Pharmacological Activation

D. Richardson, S. Sahni, S. Krishan, 2015, Molecular Pharmacology.

Nitrogen Monoxide (NO) and Glucose

D. Richardson, R. Watts, 2001, The Journal of Biological Chemistry.

Activation of an iron uptake mechanism from transferrin in hepatocytes by small-molecular-weight iron complexes: implications for the pathogenesis of iron-overload disease.

D. Richardson, A. Chua, E. Baker, 1999, The Journal of laboratory and clinical medicine.

The transferrin homologue, melanotransferrin (p97), is rapidly catabolized by the liver of the rat and does not effectively donate iron to the brain.

D. Richardson, E. Morgan, 2004, Biochimica et biophysica acta.

The iron chaperone poly(rC)-binding protein 2 forms a metabolon with the heme oxygenase 1/cytochrome P450 reductase complex for heme catabolism and iron transfer

I. Yanatori, D. Richardson, S. Toyokuni, 2017, The Journal of Biological Chemistry.

Publications for Des Richardson

D. Richardson, 2016 .

The use of iron chelators in biocidal compositions: evaluation of patent, WO2014059417A1

D. Richardson, S. Sahni, S. Krishan, 2015, Expert opinion on therapeutic patents.

Nitrogen Monoxide (NO) Storage and Transport by Dinitrosyl-Dithiol-Iron Complexes: Long-lived NO That Is Trafficked by Interacting Proteins*

D. Richardson, Y. Suryo Rahmanto, D. Kalinowski, 2012, The Journal of Biological Chemistry.

The Potent and Novel Thiosemicarbazone Chelators Di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-Benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone Affect Crucial Thiol Systems Required for Ribonucleotide Reductase Activity

D. Richardson, Yu Yu, C. Hawkins, 2011, Molecular Pharmacology.

The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation

D. Richardson, P. Ponka, Marc R. Mikhael, 2008, Proceedings of the National Academy of Sciences.

24p3 and Its Receptor: Dawn of a New Iron Age?

D. Richardson, 2005, Cell.

Glutathione-S-Transferases as Potential Targets for Modulation of Nitric Oxide-Mediated Vasodilation

D. Richardson, Tiffany M Russell, 2022, Biomolecules.

Glucose modulation induces reactive oxygen species and increases P‐glycoprotein‐mediated multidrug resistance to chemotherapeutics

D. Richardson, N. Seebacher, P. Jansson, 2015, British journal of pharmacology.

Kinetico-mechanistic studies on methemoglobin generation by biologically active thiosemicarbazone iron(III) complexes.

D. Richardson, P. Bernhardt, Manuel A Martínez, 2016, Journal of inorganic biochemistry.

Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway.

D. Richardson, J. Kwok, 2003, Molecular pharmacology.

Nitrogen monoxide decreases iron uptake from transferrin but does not mobilise iron from prelabelled neoplastic cells.

D. Richardson, P. Ponka, V. Neumannová, 1995, Biochimica et biophysica acta.

Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1

D. Richardson, P. Ponka, C. Hawkins, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Glucose Modulation Induces Lysosome Formation and Increases Lysosomotropic Drug Sequestration via the P-Glycoprotein Drug Transporter*

D. Richardson, N. Seebacher, P. Jansson, 2015, The Journal of Biological Chemistry.

Azulene hydrazide-hydrazones for selective targeting of pancreatic cancer cells.

D. Richardson, R. Kaplánek, P. Martásek, 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Examination of the mechanism of action of nitrogen monoxide on iron uptake from transferrin.

D. Richardson, R. Watts, 2000, The Journal of laboratory and clinical medicine.

Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

Sara W. Bird, Erinna F. Lee, Michael D. Kim, 2016 .

The growing evidence for targeting P-glycoprotein in lysosomes to overcome resistance.

D. Richardson, D. Kalinowski, P. Jansson, 2020, Future Medicinal Chemistry.

Iron Chelators of the Di-2-pyridylketone Thiosemicarbazone and 2-Benzoylpyridine Thiosemicarbazone Series Inhibit HIV-1 Transcription: Identification of Novel Cellular Targets—Iron, Cyclin-Dependent Kinase (CDK) 2, and CDK9

S. Nekhai, F. Kashanchi, D. Richardson, 2011, Molecular Pharmacology.

Identification of distinct changes in gene expression after modulation of melanoma tumor antigen p97 (melanotransferrin) in multiple models in vitro and in vivo.

D. Richardson, Y. Suryo Rahmanto, L. Dunn, 2007, Carcinogenesis.

The membrane‐bound transferrin homologue melanotransferrin: roles other than iron transport?

D. Richardson, E. Sekyere, Eric Sekyere, 2000, FEBS letters.

The Potential of the Novel NAD+ Supplementing Agent, SNH6, as a Therapeutic Strategy for the Treatment of Friedreich's Ataxia.

N. Braidy, D. Richardson, D. Kalinowski, 2020, Pharmacological research.

PCTH: A Novel Orally Active Chelator for the Treatment of Iron Overload Disease

D. Richardson, D. Kalinowski, P. Bernhardt, 2006, Hemoglobin.

The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.

D. Richardson, P. Ponka, 1994, Journal of Laboratory and Clinical Medicine.

Cytotoxic analogs of the iron(III) chelator pyridoxal isonicotinoyl hydrazone: effects of complexation with copper(II), gallium(III), and iron (III) on their antiproliferative activities

D. Richardson, 1997, Antimicrobial agents and chemotherapy.

Potassium Channels in Parkinson’s Disease: Potential Roles in Its Pathogenesis and Innovative Molecular Targets for Treatment

D. Richardson, R. Quinn, G. Mellick, 2023, Pharmacological Reviews.

Kinetic studies on the oxidation of oxyhemoglobin by biologically active iron thiosemicarbazone complexes: relevance to iron-chelator-induced methemoglobinemia

D. Richardson, P. Bernhardt, Manuel A Martínez, 2014, JBIC Journal of Biological Inorganic Chemistry.

Targeting Iron in Cancer Cells: A New Strategy to Inhibit Metastatic Progression

D. Richardson, Z. Kovacevic, 2012 .

Ascorbate-and iron-driven redox activity of Dp44mT and emodin facilitates peroxidation of micelles and bicelles.

D. Richardson, P. Kononova, P. Bernhardt, 2021, Biochimica et biophysica acta. General subjects.

Frataxin, a molecule of mystery: trading stability for function in its iron-binding site.

D. Richardson, D. Lane, 2010, The Biochemical journal.

Unique targeting of androgen‐dependent and ‐independent AR signaling in prostate cancer to overcome androgen resistance

D. Richardson, S. Assinder, Z. Kovacevic, 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

PotassiumChannels in Parkinson’s Disease: Potential Roles in Its Pathogenesis and InnovativeMolecular Targets for Treatment

D. Richardson, G. Mellick, Yunjiang Feng, 2023 .

Overcoming tamoxifen resistance in oestrogen receptor‐positive breast cancer using the novel thiosemicarbazone anti‐cancer agent, DpC

D. Richardson, K. Park, Rumeza Hanif, 2020, British journal of pharmacology.

Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia.

D. Richardson, E. Becker, 2001, The international journal of biochemistry & cell biology.

The effect of desferrioxamine and ferric ammonium citrate on the uptake of iron by the membrane iron-binding component of human melanoma cells.

D. Richardson, E. Baker, 1992, Biochimica et biophysica acta.

Innovative Thiosemicarbazones that Induce Multi-Modal Mechanisms to Down-Regulate Estrogen-, Progesterone-, Androgen- and Prolactin-Receptors in Breast Cancer.

D. Richardson, Robin L. Anderson, Dinny Graham, 2023, Pharmacological research.

A low-spin iron complex in human melanoma and rat hepatoma cells and a high-spin iron(II) complex in rat hepatoma cells.

T. S. St. Pierre, D. Richardson, J. Webb, 1992, Biochimica et biophysica acta.

The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis

D. Richardson, L. Dunn, E. Sekyere, 2006 .

Chaperone turns gatekeeper: PCBP2 and DMT1 form an iron-transport pipeline.

D. Richardson, D. Lane, 2014, The Biochemical journal.

Molecular Alterations in a Mouse Cardiac Model of Friedreich Ataxia: An Impaired Nrf2 Response Mediated via Upregulation of Keap1 and Activation of the Gsk3β Axis.

D. Richardson, C. Hawkins, B. E. Brown, 2017, The American journal of pathology.

Ancestral roles of eukaryotic frataxin: mitochondrial frataxin function and heterologous expression of hydrogenosomal Trichomonas homologues in trypanosomes

D. Richardson, J. Lukeš, M. Ginger, 2008, Molecular microbiology.

The Myc Family and the Metastasis Suppressor NDRG1: Targeting Key Molecular Interactions with Innovative Therapeutics

D. Richardson, Z. Deng, 2023, Pharmacological Reviews.

gene disruption in vivo Role of melanotransferrin in iron metabolism: studies using targeted

D. Richardson, L. Dunn, E. Sekyere, 2010 .

Iron chelation: deciphering novel molecular targets for cancer therapy. The tip of the iceberg of a web of iron-regulated molecules.

D. Richardson, F. Saletta, Z. Kovacevic, 2011, Future Medicinal Chemistry.

Amphiphilic hyper-branched co-polymer nanoparticles for the controlled delivery of anti-tumor agents.

D. Richardson, Yuliang Zhao, Guangjun Nie, 2010, Biomaterials.

Iron Chelators of the DpT and BpT Series Inhibit HIV-1 Transcription: Identification of Novel Cellular Targets – Iron, CDK2 and CDK9

S. Nekhai, D. Richardson, V. Gordeuk, 2010 .

Copper that cancer with lysosomal love!

D. Richardson, S. Sahni, Z. Kovacevic, 2016, Aging.

Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors.

M. Zheng, Daohai Zhang, D. Richardson, 2013, Carcinogenesis.

Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood.

P. Kuchel, D. Richardson, Y. Suryo Rahmanto, 2009, Blood.

Expanding horizons in iron chelation and the treatment of cancer: role of iron in the regulation of ER stress and the epithelial-mesenchymal transition.

D. Richardson, D. Kalinowski, N. Shafie, 2014, Biochimica et biophysica acta.

The active role of vitamin C in mammalian iron metabolism: much more than just enhanced iron absorption!

D. Richardson, D. Lane, 2014, Free radical biology & medicine.

The role of hypoxia and nitrogen monoxide in the regulation of cellular iron metabolism.

D. Richardson, 2003, The Journal of laboratory and clinical medicine.

The nitric oxide-iron interplay in mammalian cells: transport and storage of dinitrosyl iron complexes.

D. Richardson, H. Lok, 2008, Biochimica et biophysica acta.

Novel chelators for cancer treatment: where are we now?

D. Richardson, D. Kalinowski, A. Merlot, 2013, Antioxidants & redox signaling.

Chaperone turns gatekeeper: PCBP2 and DMT1 form an iron-transport pipeline.

D. Richardson, D. Lane, 2014, Biochemical Journal.

Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.

D. Richardson, Yu Yu, D. Kalinowski, 2009, Journal of medicinal chemistry.

Alkyl substituted 2'-benzoylpyridine thiosemicarbazone chelators with potent and selective anti-neoplastic activity: novel ligands that limit methemoglobin formation.

D. Richardson, D. Kalinowski, P. Bernhardt, 2013, Journal of medicinal chemistry.

D. Richardson, D. Kalinowski, Xiaozhi Zhang, 2017, Molecular Pharmacology.

The effect of impermeable oxidants on the growth of neoplastic cells

D. Richardson, V. Richardson, 1998, In Vitro Cellular & Developmental Biology - Animal.

D. Richardson, P. Ponka, J. Greer, 2013 .

Orally effective iron chelators for the treatment of iron overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs.

D. Richardson, P. Ponka, 1998, The Journal of laboratory and clinical medicine.

Structure-Activity Relationships of Di-2-pyridylketone, 2-Benzoylpyridine, and 2-Acetylpyridine Thiosemicarbazones for Overcoming Pgp-Mediated Drug Resistance.

D. Richardson, D. Kalinowski, P. Bernhardt, 2016, Journal of medicinal chemistry.

Targeting autophagy in antitumor agent design: furthering the 'lysosomal love' strategy.

D. Richardson, D. Kalinowski, S. Sahni, 2016, Future medicinal chemistry.

NDRG1: A Novel Therapeutic Target against Metastatic Cancers

D. Richardson, D. Kalinowski, Z. Kovacevic, 2015 .

The redox-active, anti-cancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism

D. Richardson, D. Kalinowski, Z. Kovacevic, 2013, Redox report : communications in free radical research.